<DOC>
	<DOCNO>NCT00941681</DOCNO>
	<brief_summary>This study design understand pharmacokinetics different oral formulation CK-1827452 consider future study patient heart failure . This study compare pharmacokinetics safety tolerability modified-release ( MR ) immediate-release ( IR ) oral formulation CK-1827452 .</brief_summary>
	<brief_title>Pharmacokinetics Oral CK-1827452 Patients With Stable Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . The patient sign Informed Consent Form/Patient Information Sheet study approve govern Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) 2 . The patient least 18 year old time consent 3 . Left ventricular ejection fraction ( LVEF ) ≤ 35 % determined Investigator within 3 week prior enrollment 4 . Treated least 4 week beta blocker ACE inhibitor ( and/or ARB ) unless tolerate . If prescribe , diuretic must administer accord consistent regimen least 4 week . 5 . Diagnosed heart failure ≥ 3 month prior enrollment 6 . Patient consider appropriate candidate study enrollment determine patient 's clinical laboratory finding , vital sign ECGs within normal range , outside normal range deem clinically significant opinion Investigator 7 . For female patient : The patient postmenopausal ( ≥ 1 year ) sterilize , childbearing potential , breastfeeding , pregnancy test negative , intention become pregnant course study , use contraceptive drug device . For male patient : Male patient agree duration study 10 week end study use condom sexual intercourse female partner reproductive potential female partner use additional effective mean contraception ( eg , diaphragm plus spermicide , oral contraceptive ) male subject must agree abstain sexual intercourse 10 week end study . 1 . Patient hospitalise heart failure , acute coronary syndrome , myocardial infarction , coronary revascularisation , transient ischemic attack stroke , cardiac arrhythmia , major surgery within 6 week prior enrollment 2 . Poorly control hypertension define blood pressure &gt; 150/95 mmHg , document least 2 separate occasion prior enrollment 3 . The patient supine heart rate ≥ 100 beat per minute 10 minute rest 4 . Patient troponin I screen upper limit normal 5 . The patient severe aortic mitral stenosis 6 . The patient active myocarditis ; clinically significant restrictive , constrictive , hypertrophic obstructive cardiomyopathy ; clinically significant congenital heart disease ; history major organ transplantation 7 . The patient Canadian Cardiovascular Society Class IV angina 8 . Patient chronic antiarrhythmic therapy , exception amiodarone 9 . Patient impair renal function define estimate GFR ≤ 30 ml/min/1.73 m2 calculate Modification Diet Renal Disease ( MDRD ) equation 10 . Patient currently take , take within 14 day prior enrollment , potent CYP3A4 inhibitor ( medication food ) . Patient currently take , take within 28 day prior enrollment , potent CYP3A4 inducer ( medication food ) . 11 . The patient hepatic impairment define total bilirubin &gt; 3 mg/dL , ALT AST &gt; 2 time upper limit normal 12 . Concomitant noncardiovascular disease expect reduce life expectancy le 1 year 13 . The patient receive investigational drug device within 30 day 5 halflives , whichever great , enrollment 14 . Patient , opinion Investigator , condition compromise ability subject give write informed consent comply study procedure , include schedule selfadministration oral CK1827452 15 . The patient prior treatment CK1827452</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>omecamtiv mecarbil</keyword>
</DOC>